Holen Sie sich die Stockscreener-App
23.06
6.02%
1.31
Handel nachbörslich:
23.07
0.01
+0.04%
Schlusskurs vom Vortag:
$21.75
Offen:
$22.59
24-Stunden-Volumen:
900.58K
Relative Volume:
0.38
Marktkapitalisierung:
$286.10M
Einnahmen:
$90.12M
Nettoeinkommen (Verlust:
$-276.06M
KGV:
-15.79
EPS:
-1.46
Netto-Cashflow:
$-193.47M
1W Leistung:
+0.44%
1M Leistung:
+1.45%
6M Leistung:
+3,311%
1J Leistung:
+1,806%
1-Tages-Spanne:
$22.01
$23.98
1-Wochen-Bereich:
$21.60
$23.98
52-Wochen-Spanne:
$0.432
$37.38
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Vergleichen Sie NKTR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
23.06 | 388.40M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-24 | Bestätigt | BTIG Research | Buy |
| 2025-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
| 2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
| 2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-09-30 | Fortgesetzt | BTIG Research | Buy |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Why Nektar Therapeutics Stock Popped 6% on Friday - MSN
Can Nektar Therapeutics expand into new marketsElite Return Strategy Watch - thegnnews.com
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y - MSN
Nektar Therapeutics Q2 2025 Earnings: Revenue Exceeds Estimates, EPS Loss Wider Than Expected, Cash and Investments Down to $175.9 Million - AInvest
Nektar Therapeutics Q2 Earnings: Revenue Down, Net Loss Up, but Cash Position Strong and FDA Fast Track Designation for Rezpegaldesleukin - AInvest
A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $98 to $120 - 富途牛牛
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates - MSN
Nektar Therapeutics 2025 Q2 Earnings Loss Narrows by 21.5% - AInvest
Nektar Therapeutics (NKTR): A High-Risk, High-Reward Biotech Play in the Treg Space - AInvest
Jonathan Zalevsky, PhD, on Rezpegaldesleukin’s Biologic Approach to Alopecia Areata - Dermatology Times
Nektar Therapeutics: Operational Efficiency Gains Amid Revenue Decline—A Path to Profitability or a Temporary Reprieve? - AInvest
Buy Rating for Nektar Therapeutics: Upcoming Catalysts and Strong Financial Performance - TipRanks
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $105 - 富途牛牛
Transcript : Nektar Therapeutics, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: Nektar Therapeutics reports Q2 2025 earnings miss By Investing.com - Investing.com Australia
Earnings call transcript: Nektar Therapeutics reports Q2 2025 earnings miss - Investing.com
Cautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical Developments - TipRanks
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Highlights: Str - GuruFocus
Nektar Therapeutics Reports Q2 2025 Financial Results - TipRanks
Nektar (NKTR) Q2 Revenue Falls 52% - The Globe and Mail
Nektar Therapeutics reports results for the quarter ended June 30Earnings Summary - TradingView
Nektar Therapeutics Q2 2025 Earnings: Revenue at $11.2M Beats Es - GuruFocus
Nektar Therapeutics: Strategic Pipeline Progress and Financial Prudence Position for Long-Term Value Creation - AInvest
Nektar Therapeutics (NKTR) Misses Q2 EPS by 258c - StreetInsider
Nektar Reports Game-Changing Atopic Dermatitis Results, Secures FDA Fast Track Status and $115M Funding - Stock Titan
Nektar gets FDA fast track status for alopecia areata drug - MSN
Nektar: Q2 Earnings Snapshot - Norwalk Hour
Nektar Therapeutics Files Amendments To Increase Authorized Common Stock From 300M To 390M Shares And Implement 1-For-15 Reverse Stock Split Effective June 8, 2025; Split-Adjusted Trading To Begin June 9, 2025 - 富途牛牛
Nektar Gears Up to Report Q2 Earnings: What's in the Cards? - MSN
FDA grants fast track designation to Nektar’s rezpegaldesleukin in alopecia areata - PMLiVE
What is the dividend policy of Nektar Therapeutics stockExplosive portfolio gains - Jammu Links News
What drives Nektar Therapeutics stock priceSignificant capital appreciation - Jammu Links News
Should I hold or sell Nektar Therapeutics stock in 2025Achieve consistent profits with proven methods - Jammu Links News
Does Nektar Therapeutics stock perform well during market downturnsAchieve breakthrough growth with proven strategies - Jammu Links News
Nektar Therapeutics (NASDAQ:NKTR) is a favorite amongst institutional investors who own 53% - uk.finance.yahoo.com
What are analysts’ price targets for Nektar Therapeutics in the next 12 monthsStrongest growth potential - Jammu Links News
What institutional investors are buying Nektar Therapeutics stockTrack stocks with high upside potential easily - Jammu Links News
Published on: 2025-08-03 06:56:13 - Jammu Links News
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets - Eastern Progress
Nektar Therapeutics' Q2 2025 Earnings: A Pivotal Moment for Its Immuno-inflammatory Pipeline and Financial Resilience - AInvest
Nektar soars on atopic dermatitis data, leads drug developer gainers in Q2 - BioWorld MedTech
Signal strength of Nektar Therapeutics stock in tech scannersSmart Trade Plans With Risk Protection Explained - metal.it
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
3.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):